BioSpace News Archive

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the execution of an agreement with MultiPlan, for participation in its PHCS and MultiPlan Networks.

Blue Earth Diagnostics Highlights Upcoming Presentation of Key Results from Phase 3 SPOTLIGHT Study of Targeted PET Imaging Agent 18 F-rhPSMA-7.3 in Biochemically Recurrent Prostate Cancer.

Advanced therapies equipment are innovative and cutting edge medical devices. These medical devices offer high efficacy levels, which has attracted significant attention and investments.

RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, announced that its collaboration partner, Acer Therapeutics, has been issued a new patent from the U.S. Patent and Trademark Office for certain claims related to ACER-001.

Sensorion is pleased to announce its participation at the 2022 Association for Research in Otolaryngology MidWinter Meeting, where it will take part in a workshop and present a poster on gene therapy.

Windtree Therapeutics, Inc. today announced it has completed enrollment in its Phase 2 study of lucinactant (KL4 surfactant) for patients with COVID-19 associated lung injury and acute respiratory distress syndrome (ARDS).

Today, Trevi announced that it has completed enrollment in its Phase 2b/3 PRISM trial for pruritus associated with prurigo nodularis (PN) and expects to report top-line data in the second quarter of 2022.

Wounds are defined as any external breakage in the continuity of the skin due to trauma or internal inflammation.

Biogen Inc. (Nasdaq: BIIB) today announced that it exercised its option to participate in the development and commercialization of mosunetuzumab.

Numinus Wellness Inc. is pleased to announce the appointment of three key advisors to its new Bioscience Advisory Board.